Methods for treating cancer using iNOS-inhibitory compositions
AssigneeThe Methodist Hospital
InventorJenny Chee Ning Chang
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for treating one or more mammalian cancers, and in particular, methods for treating human melanoma, or a head or neck cancer, that employ therapeutically-effective amounts of one or more iNOS pathway-inhibitory compounds, either alone, or in combination with one or more selected antihypertensive agents (including, for example, calcium channel antagonists), alone, or further in combination with one or more conventional chemotherapeutic agents. Also disclosed are pharmaceutical formulations that comprise these compositions, as well as methods for their use in treating refractory, metastatic, and/or relapsed cancers, or, for use in the management or reversal of treatment resistance in one or more such mammalian cancers.
Claims24
A method of treating or ameliorating one or more symptoms of melanoma or a head/neck cancer in an animal in need thereof, the method comprising administering to the animal (a) a composition comprising:
- 1) a therapeutically-effective amount of NG-monomethyl-L-arginine [L-NMMA];
- 2) a therapeutically-effective amount of amlodipine;
- and
- 3) a therapeutically-effective amount of a first chemotherapeutic agent;
- for a time sufficient to treat or ameliorate the one or more symptoms of melanoma or the head/neck cancer in the animal.
A method of treating or ameliorating one or more symptoms of melanoma in a mammal, comprising:
- systemically administering to the mammal a composition that comprises:
- therapeutically-effective amounts of:
- a) NG-monomethyl-L-arginine [L-NMMA];
- b) amlodipine;
- and docetaxel;
- for a time sufficient to treat or ameliorate the one or more symptoms of melanoma in the mammal.
A method of treating or ameliorating one or more symptoms of a head/neck cancer in a mammal, comprising:
- systemically administering to the mammal a composition that comprises:
- therapeutically-effective amounts of:
- a) NG-monomethyl-L-arginine [L-NMMA];
- b) amlodipine;
- and docetaxel;
- for a time sufficient to treat or ameliorate the one or more symptoms of the head/neck cancer in the mammal.
A method of treating or ameliorating one or more symptoms of melanoma or a head/neck cancer in a mammal in need thereof, the method comprising administering to the animal:
- (a) a composition comprising:
- 1) a therapeutically-effective amount of NG-monomethyl-L-arginine (L-NMMA);
- 2) a therapeutically-effective amount of amlodipine;
- and
- 3) a chemotherapeutically-effective amount of docetaxel,
- for a time sufficient to treat or ameliorate the one or more symptoms of melanoma or the head/neck cancer in the mammal.
Dependencies are inferred from the claim text.